Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
J Exp Med. Apr 20, 1998; 187(8): 1235–1247.
PMCID: PMC2212237
Articles

Involvement of Bruton's Tyrosine Kinase in FcεRI-dependent Mast Cell Degranulation and Cytokine Production

Abstract

We investigated the role of Bruton's tyrosine kinase (Btk) in FcεRI-dependent activation of mouse mast cells, using xid and btk null mutant mice. Unlike B cell development, mast cell development is apparently normal in these btk mutant mice. However, mast cells derived from these mice exhibited significant abnormalities in FcεRI-dependent function. xid mice primed with anti-dinitrophenyl monoclonal IgE antibody exhibited mildly diminished early-phase and severely blunted late-phase anaphylactic reactions in response to antigen challenge in vivo. Consistent with this finding, cultured mast cells derived from the bone marrow cells of xid or btk null mice exhibited mild impairments in degranulation, and more profound defects in the production of several cytokines, upon FcεRI cross-linking. Moreover, the transcriptional activities of these cytokine genes were severely reduced in FcεRI-stimulated btk mutant mast cells. The specificity of these effects of btk mutations was confirmed by the improvement in the ability of btk mutant mast cells to degranulate and to secrete cytokines after the retroviral transfer of wild-type btk cDNA, but not of vector or kinase-dead btk cDNA. Retroviral transfer of Emt (= Itk/Tsk), Btk's closest relative, also partially improved the ability of btk mutant mast cells to secrete mediators. Taken together, these results demonstrate an important role for Btk in the full expression of FcεRI signal transduction in mast cells.

Mast cells and basophils play pivotal roles in the initiation of allergic reactions. Cross-linking of the high-affinity receptor for IgE (FcεRI) on these cells activates intracellular signaling pathways that lead to degranulation and release of histamine and other preformed mediators, de novo synthesis and release of lipid mediators, and secretion of preformed and de novo synthesized cytokines (1, 2). These bioactive mediators are thought to lead to allergic inflammation.

FcεRI consists of one molecule of an α subunit that is capable of binding to IgE, one molecule of a β subunit with four transmembrane segments, and two molecules of disulfide-bonded γ subunits (3). None of these subunits have discernible enzyme structures, but both the β and γ subunits have the immunoreceptor tyrosine-based activation motif (ITAM; references 4, 5).1 After FcεRI cross-linking, tyrosine phosphorylation of several intracellular proteins is the earliest recognizable activation event (6). The importance of protein tyrosine kinases (PTKs) in FcεRI-mediated mediator secretion has been demonstrated by showing that treatment with a variety of PTK inhibitors can abrogate FcεRI-dependent activation of mast cells (7, 8). Two specific PTKs, Lyn and Syk, that belong to the Src and Syk/ZAP families, respectively, were shown to be essential for FcεRI-mediated mast cell activation (911). According to a generally accepted hypothesis (12), Lyn that is associated with the β subunit in unstimulated cells is activated upon FcεRI cross-linking. Subsequently, activated Lyn phosphorylates tyrosine residues within the ITAM sequences in the β and γ subunits. Phosphorylated ITAM (phospho-ITAM) in the β subunit recruits new molecules of Lyn through the Src homology 2 (SH2) domain–phosphotyrosine interaction while phospho-ITAM in the γ subunit recruits Syk by the same mechanism (13). Lyn and Syk are activated when bound to phospho-ITAMs (14, 15), and such activated Lyn and Syk in turn phosphorylate downstream targets such as phospholipase C (PLC)–γ.

Three Tec family PTKs, Btk, Emt/Itk/Tsk (Emt), and Tec, are also expressed in mast cells (16, 17). Among them, Btk and Emt are activated upon FcεRI cross-linking, suggesting a functional role in mast cell activation (18, 19). However, in contrast with Lyn and Syk (2022), these PTKs do not appear to be receptor-associated molecules. Moreover, both Btk and Emt have important roles that are apparently unrelated to their involvement in FcεRI-dependent mast cell activation. Thus, Btk plays an essential role in the differentiation and activation of B lymphocytes: defects in the btk gene lead to X-linked agammaglobulinemia in humans (23, 24) and X-linked immunodeficiency (xid) in mice (25, 26). In addition, subsequent studies have implicated Btk in a number of signal transduction pathways in immune cells, including those for the B cell antigen receptor (2729), CD38 (30, 31), CD40 (32), IL-5 (33), IL-6 (34), and IL-10 (35). Emt is considered a “T cell equivalent” of Btk, and is involved in T cell development and early activation events triggered through TCR/CD3 and CD28 (3638).

Both xid (a mutation which results in the substitution of Arg with Cys at residue 28 in the Btk protein) and btk null mice exhibit essentially the same phenotype: these mutations lead to reduced numbers of mature conventional B cells, a severe deficiency of B1 B cells, a deficiency of serum IgM and IgG3, and defective responses to various B cell activators in vitro and to immunization with thymus-independent type II antigens in vivo (39, 40).

In this study, we analyzed Btk functions in mast cells in vivo and in vitro. Although btk mutant mast cells appear normal in many aspects of development in vitro or in vivo, they exhibited multiple abnormalities in FcεRI-mediated functions. Btk mutant mast cells exhibited mild to moderate impairment of FcεRI-mediated degranulation and histamine release, and more severe impairment of FcεRI-mediated cytokine production in vitro. Btk mutant mice exhibited correspondingly mild versus severe abnormalities in the early versus late phases of FcεRI-mediated cutaneous inflammatory responses in vivo. Furthermore, we found that both xid and null mutations of the btk gene result in defects in the transcriptional regulation of cytokine genes in mast cells stimulated via FcεRI, and such defects in btk mutant mast cells could be improved by retroviral gene transfer of wild-type (wt) btk cDNA. These results collectively demonstrate the involvement of Btk in the full expression of FcεRI signal transduction.

Materials and Methods

Passive Cutaneous Anaphylactic (PCA) Reactions.

In homologous PCA experiments, 10 μl of various amounts of anti-DNP monoclonal IgE was intradermally injected into the ear of mice. 24 h later, 0.25 ml saline solution containing 1 mg/ml DNP conjugates of BSA (DNP8.7-BSA) and 0.5% Evans blue dye was intravenously injected. The amounts of extravasated dye were measured after 30 min by extracting ears with potassium hydroxide as previously described (41). In another type of experiment, CBA/J and CBA/CaHN-xid/J mice received 1.0 ml anti-DNP monoclonal IgE antibody intravenously. 24 h later, a skin reaction was elicited by applying 10 μl 0.75% dinitrofluorobenzene acetone– olive oil solution to both sides of the ears. The reaction was assessed by measuring the ear thickness using an engineer's micrometer, Upright Dial Gauge (Peacock, Tokyo, Japan), at the indicated times after antigen challenge (42).

Cell Culture and Stimulation.

Bone marrow cells taken from mouse femurs were incubated in the presence of IL-3 as previously described (7). After 4 wk of culture, cells (>95% mast cells, termed BMMCs for bone marrow–derived cultured mast cells) were incubated overnight with anti-DNP IgE antibody. Unless otherwise indicated (e.g., in cells stimulated for release of histamine or leukotrienes, see below), sensitized cells were stimulated for 24 h with 30 ng/ml DNP conjugates of human serum albumin (DNP-HSA) in RPMI 1640 medium supplemented with 10% fetal bovine serum, 50 μM 2-ME, 2 mM glutamine, and IL-3. For most retroviral transfection experiments, bone marrow cells cultured in the presence of IL-3 for 2–3 wk were expanded in the presence of both IL-3 and recombinant rat stem cell factor (SCF; gift of Kirin Brewery Co., Tokyo, Japan) for another 1–2 wk. At this point, >95% of the cells were mast cells, termed sBMMCs (for SCF-maintained BMMCs).

Northern Blot Analysis.

Total cellular RNAs were isolated using RNAzol B (Tel-Test, Inc., Friendswood, TX) according to the manufacturer's instructions. RNAs fractionated by formaldehyde/agarose gel electrophoresis were blotted onto nitrocellulose membranes. Mouse TNF-α (obtained from the American Type Culture Collection, Rockville, MD) and c-myc (a gift from D.R. Green, La Jolla Institute for Allergy and Immunology, La Jolla, CA) cDNA fragments were gel-purified and 32P-labeled with a Megaprime DNA labeling kit (Pharmacia Biotech, Piscataway, NJ). Membranes were hybridized with 32P-labeled probe purified through Elutip-d (Schleicher & Schuell, Keene, NH). Hybridized bands were detected by autoradiography.

Immunoblot Analysis.

Immunologically stimulated cells were lysed in 1% NP-40–containing buffer. Cleared lysates were directly analyzed by SDS-PAGE or immunoprecipitated with polyclonal anti–TNF-α antibodies (Genzyme Corp., Cambridge, MA) before SDS-PAGE. Proteins in gels were electrophoretically transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA). Membranes were blocked, incubated with anti–TNF-α, anti-Btk (43), anti-Emt (44), or other appropriate primary antibodies, and then with horseradish peroxidase–conjugated secondary antibody. Immunoreactive bands were detected by an enhanced chemiluminescence kit (Amersham Corp., Arlington Heights, IL).

Transfection.

Murine btk cDNA in pME18S vector (16) was used for in vitro mutagenesis using two-step PCR procedures (45) to generate K430R and other btk mutants. The wt and mutant btk cDNAs confirmed by sequencing were inserted into the Moloney murine leukemia virus–based retroviral vectors, pMX-neo or pMX-puro (46). Retroviruses were generated by transient transfection of BOSC-23 packaging cells (47) with Lipofectamine (GIBCO BRL, Gaithersburg, MD). BMMCs or sBMMCs derived from male xid or btk null mice were infected with these retroviruses in the presence of 10 μg/ml polybrene. Selection with G418 (for xid-BMMCs and xid-sBMMCs) or puromycin (for btk null–BMMCs and btk null–sBMMCs) was started 48 h after infection. Mass populations of G418- or puromycin-resistant cells were grown and then cultured in the absence of selection drug for 48 h before immunological stimulation.

Measurements of Secreted Histamine, Cytokines, and Leukotrienes.

Histamine released into the media during a 45-min stimulation was measured by an automatic fluorometric assay (48). Concentrations of antigen (ED50) for half maximal histamine release was estimated using 77% (wt) and 79% (xid) as maximal responses. TNF-α, IL-2, IL-4, IL-6, and GM-CSF secreted into the media for 24 h were measured by ELISA kits (Endogen, Woburn, MA). Leukotrienes secreted into media for 30 min were analyzed by an enzyme immunoassay kit for leukotriene C4/D4/E4 (Amersham Corp.).

Transcriptional Activity Assay with Luciferase Reporter Constructs.

Luciferase reporter constructs, mouse IL-2 (−321), nuclear factor of activated T cells (NFAT)d–luc, NFκB–luc, and c-fos–luc have been previously described (49, 50). To engineer the human TNF-α (−200)–luc, PCR was done to amplify a DNA fragment containing the TNF-α promoter region (−199 to +68). This PCR fragment was inserted into the SmaI/BglII site of pGL3-Basic vector (Promega Corp., Madison, WI). 1.0–1.5 × 107 mast cells were transfected with 5–10 μg reporter plasmids by electroporation at 400 V, 950 μF using a Gene Pulser II apparatus (Bio-Rad, Hercules, CA). Transfected cells were sensitized with anti-DNP monoclonal IgE antibody overnight, and left unstimulated or stimulated with 30 ng/ml DNP-HSA for 8 h before cell harvest. Cells were lysed in 0.2% Triton X-100 in 100 mM potassium phosphate buffer (pH 7.8)/1 mM dithiothreitol. Luminescence of cleared lysates was measured after addition of luciferin solution using a luminometer (Monolight 2010; Analytical Luminescence Laboratory, San Diego, CA).

Quantitation of Tissue Mast Cells.

Tissue mast cells in ear skin were quantified by light microscopy at ×400 by an observer who was unaware of the identity (i.e., mouse genotype) of the individual specimens, in 1-μm, Epon-embedded, Giemsa-stained sections, as previously described (51). Results were expressed as mast cells (mean ± SEM) per mm2 of dermis (51).

Results

Mast Cell Development Is Not Affected by btk Mutations.

First, we assessed the effects of btk null and xid mutations on several aspects of mast cell development and phenotype in vivo or in vitro. Mast cells in wt and btk null mouse ear skins were similar in their morphology and anatomical distribution (data not shown) and numbers: 125 ± 27.9/mm2 of dermis (129/C57BL F2) versus 123 ± 32.2/mm2 of dermis (btk null). The phenotypes of BMMCs were indistinguishable between wt (CBA/J) and xid (CBA/HCaN-xid/J) as well as between wt (129/C57BL F2) and btk null mice in their morphology when the cells were stained with May-Giemsa or with Alcian Blue (data not shown), and in numbers of IgE binding sites: (4.6 ± 1.2) × 104/cell (CBA/J) versus (3.7 ± 2.0) × 104/cell (CBA/HCaN-xid/J); (7.9 ± 2.4) × 104/cell (129/C57BL F2) versus (8.2 ± 2.9) × 104/ cell (btk null). The wt- and btk null–BMMCs were similar in the expression of various signaling proteins, including FcεRI β and γ subunits, Lyn, Syk, Grb2, Shc, Sos, H-Ras, PLC-γ1, SPY75 (= HS1), protein kinase C (PKC; α, βI, βII, δ, ε, η, θ, and ζ isoforms), ERK1/2, JNK1/2, p38, PAK65, SEK1, and c-Jun (data not shown). Therefore, we concluded that either btk null or xid mutations apparently do not significantly interfere multiple aspects of mast cell development in vivo and in vitro.

Effects of btk Mutations on Anaphylactic Reactions In Vivo.

We next tested the effects of the btk mutations on mast cell activation events induced by FcεRI cross-linking. Two types of PCA experiments were carried out. Mice primed by intradermal injection of anti-DNP IgE for 24 h were injected intravenously with antigen and Evans blue dye. Extravasation of Evans blue dye, due to increased blood vessel permeability as a result of PCA reactions, was quantified. The extravasation of Evans blue dye during the first 30 min of the PCA reactions, which is dependent mainly on histamine and serotonin released from activated mast cells (52), was slightly but significantly reduced at all the tested IgE doses in xid mice compared with wt mice (Fig. (Fig.11 A). To examine another type of PCA reaction (42), mice were sensitized with anti-DNP IgE 24 h before a solution of 0.75% dinitrofluorobenzene (hapten) was applied epicutaneously to the ear skin. xid mice exhibited little or no IgE/ antigen-specific edema, whereas wt mice exhibited a prominent response that was detectable 4 h or later after antigen stimulation (Fig. (Fig.11 B). This late reaction is known to be at least partly due to TNF-α secreted from activated mast cells (51). Indeed, injection into the PCA-inducing site of wt mice with a neutralizing antibody to TNF-α just before antigen application significantly suppressed the development of the edema associated with the late phase of the reaction, as measured 24 h after antigen stimulation (Fig. (Fig.11 C). Significant defects in both the early and late phases of PCA reactions were also observed in btk null mice (data not shown).

Figure 1Figure 1Figure 1
PCA reactions in CBA/J (wt) and CBA/CaHN-xid/J (xid) mice. (A) Mice were left unsensitized [PCA(-)] or sensitized by intradermal injection of the indicated amounts of anti-DNP IgE in 10 μl solution at the ear 24 h before antigen challenge. Mice ...

Effects of btk Mutations on FcεRI-mediated Degranulation and Cytokine Secretion.

To investigate the cellular basis for the diminished PCA reactions in btk mutant mice, the capacities to degranulate and release histamine and to produce and secrete cytokines were compared between BMMCs derived from the wt mice and the xid (or btk null) mice. Consistent with the modest defect in the early phase of PCA reactions and the more striking defect in the later phase, xid-BMMCs showed relatively mild defects in FcεRI-elicited histamine release but more severe impairments in cytokine secretion compared with wt-BMMCs. Maximal histamine responses (70–80% of the cellular content) were similar between wt- and xid-BMMCs. However, xid-BMMCs exhibited a marked reduction in histamine release at suboptimal doses of antigen, and the sensitivity of xid-BMMCs to antigen stimulation was reduced by 3.8-fold compared with wt-BMMCs (ED50 = 4.4 ng/ml [wt] versus 17 ng/ml [xid], see Fig. Fig.22 A). Btk null–BMMCs exhibited a somewhat more severe defect with a reduction in maximal histamine release in addition to reduced antigen sensitivity (Fig. (Fig.22 B).

Figure 2Figure 2
FcεRI-induced histamine release and cytokine secretion from wt and xid-BMMCs. BMMCs were sensitized by overnight incubation with 1 μg/ml anti-DNP monoclonal IgE antibody. Cells resuspended in Tyrode solution (A and B) or culture media ...

In contrast to the relatively mild defect in histamine release, the differences in TNF-α secretion between the xid- and wt-BMMCs stimulated with an optimal concentration (30 ng/ml) of antigen ranged between 1:3.2 and 1:12 (a mean of 1:6.7, n = 5, see Fig. Fig.22 C). FcεRI-stimulated secretion of IL-2, IL-6, and GM-CSF was also impaired to a similar extent in xid-BMMCs (Fig. (Fig.22 C and data not shown). Similarly reduced cytokine responses were observed in btk null cells (data not shown). Wt-, xid-, and btk null–BMMCs secreted barely detectable amounts (<40 pg/ml) of IL-4 in response to an immunologic stimulation through FcεRI (data not shown). These results suggest that the abnormalities in the expression of PCA reactions in xid and btk null mice reflect the mildly reduced degranulation and markedly defective cytokine secretion exhibited by btk mutant mast cells upon FcεRI cross-linking.

Defects in the Transcription of Cytokine Genes in btk Mutant Mast Cells.

To further characterize the defects in TNF-α production and secretion in xid-BMMCs, we analyzed levels of TNF-α mRNA and protein in xid- and corresponding wt-BMMCs. As revealed by Northern blotting (Fig. (Fig.33 A), in wt-BMMCs, TNF-α mRNA was almost undetectable before stimulation but increased dramatically within 1 h after FcεRI cross-linking and decreased within the next few hours. However, under the same conditions of stimulation, xid-BMMCs produced less than one fifth the amount of TNF-α mRNA at its peak.

Figure 3Figure 3
Analysis of TNF-α mRNA and protein in wt and xid mast cells. (A) Northern blot analysis for TNF-α mRNA of total cellular RNAs from immunologically stimulated BMMCs (top). The same blot was reprobed with c-myc cDNA (bottom). FcεRI ...

The membrane-bound TNF-α precursor (53), which was barely detectable before stimulation, increased after FcεRI cross-linking and reached a plateau level by 2–3 h after stimulation in wt-BMMCs (Fig. (Fig.33 B and data not shown). However, stimulation of xid-BMMCs led to only a slight increase in membrane-bound TNF-α content. Cellular pulse and chase experiments with [35S]methionine showed that there was no significant difference in the intracellular stability of TNF-α protein between wt- and xid-BMMCs (data not shown).

Taken together, these data suggest that Btk regulates TNF-α production at the transcriptional level. To test this possibility directly, we transfected BMMCs with luciferase reporter constructs under the control of TNF-α or IL-2 promoters. Transcription of both the TNF-α and IL-2 reporter constructs was strongly induced when wt-BMMCs were stimulated by FcεRI cross-linking. In btk null–BMMCs, the induced transcriptional activity of the TNF-α (−200)– luc construct was ~50% of that in wt-BMMCs (Fig. (Fig.44 A). Induction of transcriptional activities of the IL-2 (−321)– luc construct was 4–5-fold less in btk null–BMMCs compared with its activity in wt cells (Fig. (Fig.44 A). Similar results were obtained when the transcriptional activity of the TNF-α and IL-2 constructs was assessed in xid- versus wt-BMMCs (data not shown). We then performed additional experiments to assess the specificity of the transcriptional regulation of cytokine genes by Btk. We found that btk null–sBMMCs that had been stably transfected with wt btk exhibited higher transcriptional activities of the IL-2 (−321)–luc, TNF-α (−200)–luc, and NFAT–luc constructs than the cells transfected with vector or kinase-dead (K430R) btk (Fig. (Fig.44 B). By contrast, all three cell populations exhibited similar low levels of activity for the NFκB and c-fos constructs (Fig. (Fig.44 B).

Figure 4Figure 4
Transcriptional activity of luciferase reporter constructs in wt mast cells or btk null mast cells reconstituted with wt or K430R btk cDNAs. Promoter reporter constructs, IL-2 (−321)–luc, TNF-α (−200)–luc, NFAT–luc, ...

The NFAT family of transcription factors and AP-1 proteins play essential roles in the expression of the IL-2 (54, 55) and TNF-α genes (5658). These results indicate that defects in the production/secretion of cytokines upon FcεRI cross-linking in btk mutant mast cells are due, at least in part, to the inefficient transcription of these genes and may involve the signal transduction pathways leading to the activation of NFAT and/or AP-1 (Jun–Fos or Jun– Jun dimers). This notion is consistent with our recent data that Btk regulates JNK, an activator of c-Jun (59).

Gene Transfer–mediated Enhancement of the Ability of btk Mutant Mast Cells to Secrete Cytokines and Degranulate.

To further investigate the relationship between btk mutations and impairment of mast cell functions, we measured cytokine production in btk mutant mast cells that had been reconstituted with Btk by stable or transient transfection. For most of these experiments, we used mast cells (sBMMCs) that had been expanded in the presence of both IL-3 and SCF. When xid-sBMMCs that had been transfected with wt btk cDNA were stimulated by FcεRI cross-linking, we observed a substantial enhancement of TNF-α–producing/ secretory ability as compared to that seen in xid-sBMMCs that had been transfected with neo vector alone, with xid or kinase-dead (K430R) mutant btk cDNAs, or with wt syk or wt lyn cDNAs (Fig. (Fig.55 A). Expression of the transfected genes at comparable levels was confirmed by increased immunoreactive Btk proteins in wt, xid, and K430R mutant btk–transfected cells (Fig. (Fig.55 D, left). Transfectants expressing the constitutively active Btk* protein with the E41K substitution (60) exhibited somewhat higher levels of TNF-α secretion than did wt btk transfectants (Fig. (Fig.55 A). Moreover, none of the nontransfected or transfected sBMMCs secreted TNF-α without FcεRI stimulation (data not shown). Results similar to those shown for TNF-α secretion were also obtained when we tested the effects of transfection with wt versus various mutant btk cDNAs on the ability of FcεRI-stimulated xid-sBMMCs to secrete IL-2, IL-6, and GM-CSF (data not shown).

Figure 5Figure 5Figure 5Figure 5
Effects of retroviral transfection of btk cDNAs on the ability of xid or btk null mast cells to produce cytokines or degranulate. (A) xid-sBMMCs were infected with the retroviruses encoding wt, kinase-dead (K430R), xid, or E41K mutant btk cDNAs. As controls, ...

We next investigated btk null–sBMMCs transfectants, and in particular analyzed the domain requirements for Btk function in FcεRI-mediated cytokine production as opposed to degranulation. As shown in Fig. Fig.55 B, transfection with wt btk cDNA greatly enhanced the ability of the cells to produce TNF-α, IL-2, IL-6, or GM-CSF in response to FcεRI-dependent activation, whereas compared with transfection with vector, transfection with kinase-dead (K430R) or SH2 mutant (R307K) btk cDNA had little or no effect. On the other hand, relatively low levels of protein expression for the product of the SH2 mutant (R307K) were detected in the stably transfected cells (Fig. (Fig.55 D, middle), indicating that the potential effects of this mutant btk in this system have not yet been adequately tested. Notably, transient transfection of btk null–sBMMCs with wt, but not kinase-dead, btk also restored cytokine gene transcriptional activities (data not shown). This finding provides further support for the conclusion that the results reflect the role of Btk in FcεRI signaling, not any role it might have in mast cell differentiation.

Notably, two mutant Btk proteins appeared to be able to partially (for TNF-α, IL-2 and GM-CSF) or fully (for IL-6) normalize 24-h cytokine production with respect to that seen in cells that had been transfected with wt btk cDNA (Fig. (Fig.55 B). One of these, the P265L mutation in the SH3 domain, is equivalent to the function-negative mutation in the SH3 domain of sem-5 (61). Therefore, this result suggests that at least partial FcεRI-dependent cytokine secretory function can be expressed in the absence of normal Btk SH3 function.

The other mutant btk cDNA that partially restored cytokine secretory ability in btk null–sBMMCs was xid (Fig. (Fig.55 B). This result may be related to the fact that levels of xid Btk protein in btk null–sBMMCs that had been transfected with xid btk cDNA were ~20–30% greater than levels of wt Btk protein in the corresponding wt btk transfectants (by contrast, xid-BMMCs express only 1/5 to 1/3 the amount of Btk protein as do wt-BMMCs, data not shown). Thus, in comparison to xid-BMMCs, btk null–sBMMCs that had been transfected with xid btk cDNA greatly overexpress the xid Btk.

We previously noted (in Fig. Fig.2)2) that the defect in FcεRI-dependent degranulation and histamine release exhibited by xid-BMMCs was less severe than that observed with btk null–BMMCs. Indeed, at optimal levels of FcεRI-dependent stimulation, xid-BMMCs gave a histamine release response that was indistinguishable from that of the corresponding wt-BMMCs (Fig. (Fig.22 A). We therefore examined the effect of transfection of btk null–sBMMCs with xid btk and other mutant btks, as opposed to wt btk, on degranulation (as assessed by histamine release) at optimal conditions of IgE sensitization and antigen challenge (Fig. (Fig.55 C). We found that the profound defect in the histamine release response of btk null–sBMMCs under these conditions was nearly fully restored by wt or xid btk cDNAs, was slightly enhanced by SH2 (R307K) or SH3 (P265L) mutant btk cDNAs, but was unaffected (relative to results obtained with vector alone) by the kinase-dead (K430R) mutant btk cDNA (Fig. (Fig.55 C).

Since Emt is not only closely related to Btk but is activated upon FcεRI cross-linking (19), we also examined whether Emt might influence defects in cytokine production or degranulation in btk null–sBMMCs. We found that btk null–sBMMCs express endogenous Emt protein (Fig. (Fig.55 D). Moreover, the overexpression of wt Emt protein, but not kinase-dead (K390R) Emt protein, enhanced both FcεRI-dependent cytokine production (Fig. (Fig.55 B) and histamine release (Fig. (Fig.55 C) in btk null–sBMMCs. However, transfection of btk null–sBMMCs with wt emt did not restore either cytokine production or histamine release to levels observed in cells which had been transfected with wt btk (Fig. (Fig.5,5, B and C).

Discussion

Btk Functions in Mast Cells and Other Hematopoietic Cells.

Btk has been shown to have essential roles in B cell differentiation and activation. Although our in vivo and in vitro studies have thus far revealed no significant effects of the btk mutations on mast cell development, we have identified multiple defects in FcεRI-induced activation events in btk mutant mast cells. Both degranulation, leading to release of histamine, and production/secretion of several cytokines were mildly or severely impaired, respectively. These defects at the cellular levels probably account for the defective expression of anaphylactic reactions in response to IgE and antigen in btk mutant mice. Together with our previous data demonstrating the tyrosine phosphorylation and enzymatic activation of Btk upon FcεRI cross-linking (18), these in vivo and in vitro effects of btk mutations have established that Btk has a role in the expression of FcεRI-dependent mast cell function.

Notably, some of the effects of btk mutations are milder in mice than in humans. For example, X-linked agammaglobulinemia patients have few mature B cells with no or little immunoglobulin production, whereas xid or btk null mice have about half the number of B cells as in normal mice (39, 40, 62, 63). Such species differences in the consequences of btk mutations raise the possibility that the effects of btk mutations on mast cell development or function might be milder in mice than in humans. This possibility is currently being investigated.

The btk gene is also expressed in myeloid cells in addition to mast and B cells (16). Hence, we examined the ability of activated macrophages from btk mutant mice to secrete TNF-α. We found that lipopolysaccharide stimulation induced the secretion of indistinguishably high levels of TNF-α from wt versus xid mouse bone marrow–derived macrophages (98% Mac-1+) cultured in GM-CSF (data not shown). Therefore, the production/secretion of TNF-α seems to be differentially regulated in the two types of cells; it is more dependent on Btk in mast cells than in macrophages. This is not surprising, given the recent data demonstrating that the transcription of the TNF-α gene is regulated in a cell type–specific manner in activated T and B cells (58).

Structural Requirements of Btk for FcεRI-dependent Degranulation and Cytokine Production/Secretion.

Btk and Emt have, in order from their NH2 to COOH termini, pleckstrin homology (PH), Tec homology (TH), SH3, SH2, and SH1 (= kinase) domains. The catalytic activity of Btk was critical for mast cells to exhibit fully normal degranulation and production/secretion in response to FcεRI stimulation. In accord with this finding, transfection of xid-sBMMCs with a constitutively active form of Btk, Btk* with E41K mutation (60), resulted in the secretion of even higher levels of TNF-α than did transfection of the cells with wt Btk (Fig. (Fig.55 A). Interestingly, an SH3 mutant (P265L) could induce at least partial restoration of cytokine producing/secretory capacity. Therefore, an intact SH3 domain does not appear to be required for the expression of at least some Btk function in this system.

Remarkably, we also found that xid (R28C mutation in the PH domain) Btk, when overexpressed, could, depending on the cytokine, partially or apparently fully restore the cytokine producing/secretory capacity in both xid and btk null mast cells. The requirement of Btk domains for degranulation is similar to that for cytokine producing/secretory capacity (Fig. (Fig.5,5, A–C). Interestingly, xid Btk overexpressors released histamine as efficiently as wt Btk transfectants upon FcεRI cross-linking with an optimal concentration of antigen (Fig. (Fig.55 C). At first glance, these results appear inconsistent with the finding that xid mast cells express defects in FcεRI-dependent function. However, xid-BMMCs express only 1/5 to 1/3 as much Btk protein as do wt-BMMCs. By contrast, btk null–sBMMCs that had been transfected with xid btk cDNA expressed 20–30% more Btk protein than did cells transfected with wt btk cDNA, and both types of transfectant greatly overexpressed Btk protein relative to levels in xid-BMMCs. Finally, the defects in FcεRI-dependent mast cell function in xid-BMMCs are less severe than those in the btk null–BMMCs; in fact, at optimal concentrations of antigen challenge, xid-BMMCs released histamine at levels that were indistinguishable from those of wt-BMMCs (Fig. (Fig.22 A). Taken together with the results obtained with the kinase-dead and SH3 mutants, these results suggest that the kinase activity of Btk is strictly required for Btk function in degranulation and cytokine production and secretion, but that other domains, such as the PH and SH3 domains, are not as essential for these functions of Btk in mast cell activation.

Several Btk-associated molecules have been described. PH domain–binding molecules include phosphatidylinositol 4,5-bisphosphate (and related phosphoinositides; references 6466), the β subunits of GTP-binding proteins (67, 68), PKC (43), and BAP-135 (69). A proline-rich sequence in the Tec homology domain binds SH3 domains of Src family PTKs (70, 71), whereas the SH3 domain of Btk interacts with a protooncogene product, p120c-cbl (72). Differential binding requirements of some of PH domain–associated signaling molecules may account for the observed differences in the biochemical capacities or biological functions of xid versus wt Btk.

We found that wt, but not kinase-dead (K390R), Emt could partially compensate for the absence of Btk in the expression of FcεRI-dependent mast cell degranulation and cytokine production/secretion. Emt protein levels in wt and btk null mast cells, as revealed by immunoblotting with an anti-Emt polyclonal antibody that cross-reacts with Btk, were estimated to be ~10% of the Btk level in wt mast cells (Fig. (Fig.55 D), assuming that the antibody binds to Emt and Btk with the same efficiency. Given this finding and the results of our emt transfection experiments, it is possible that the retention of limited degranulation and cytokine production capacity in xid or btk null mutant mast cells may reflect low-level expression of Emt (and/or other Tec family PTKs) in these cells. This possibility remains to be investigated using mast cells devoid of both Btk and Emt (and/or other Tec family) proteins.

Btk Regulates the Transcription of Several Cytokine Genes.

The abnormalities in the production/secretion of cytokines in btk mutant mast cells seem to be at the transcriptional level. Thus, levels of TNF-α mRNA induced by FcεRI cross-linking in wt mast cells exceeded that in xid mast cells by at least fivefold. This difference in mRNA levels could be due to differences in the transcription rate and/or in the mRNA stability, both phenomena known for IL-2 and other cytokines (73). In addition, the TNF-α mRNA has AU-rich sequences at the 3′ untranslated region that predispose for mRNA degradation and repress its translation (7476). Although the possibilities of differential cytokine mRNA stabilities and differential derepression of mRNA translation between wt and btk mutant mast cells are not ruled out by this study, the notion of Btk-mediated regulation of cytokine gene transcriptions can account largely for our data. Thus, promoter reporter assays using the constructs without the 3′ AU-rich sequences demonstrated significant differences between wt and btk mutant mast cells in the transcriptional activity of the TNF-α and IL-2 promoters and individual cis-elements (see below) upon FcεRI cross-linking. By contrast, we found that the xid mutation had little or no detectable effect on the posttranslational regulation of TNF-α expression. All of these data are consistent with the fact that the expression of this cytokine is regulated at the transcriptional level by the activation of critical transcription factors in activated T and B cells (56– 58, 77).

Similar observations were made with promoter reporter constructs to examine individual cis-acting elements. Thus, NFAT activity was activated by FcεRI stimulation, as previously shown in a mast cell line, CPII (78). However, FcεRI-induced transcriptional activation of an NFAT–luciferase construct was lower in btk null cells than in wt cells. In contrast, NFκB–luciferase and c-fos–luciferase activities were induced (at relatively low levels) by FcεRI stimulation, but the extent of transcriptional activation of these constructs was similar in wt versus btk null mast cells (data not shown). These observations are consistent with the results obtained with btk null mast cells that had been transfected with vector, wt btk, or kinase-dead btk cDNAs (Fig. (Fig.44 B). NFATp binds to four sites in the TNF-α promoter (58). Together with NFAT, the CRE site just upstream of κ3, an NFATp-binding site, binds c-Jun and ATF-2 transcription factors to activate this gene in response to TCR/CD3 stimulation (57, 58). NFATp binds to five sites in the IL-2 gene promoter (55) and cooperatively binds with c-Fos– c-Jun heterodimers or c-Jun–c-Jun homodimers at these sites (55, 79). Thus, it is likely that the regulation of the TNF-α and IL-2 genes in mast cells also involves NFAT and AP-1 proteins.

Btk-dependent Signaling Pathways.

Btk is activated by the phosphorylation of tyrosine-551 by Lyn (80). Activated Btk in turn autophosphorylates Tyr-223 in the SH3 domain (81). Chicken DT-40 B lymphoma cells in which the btk gene was knocked out exhibited reduced tyrosine phosphorylation of PLC-γ2 and little [Ca2+]i rise in response to anti-IgM stimulation, suggesting a role of Btk in the regulation of intracellular Ca2+ concentrations through direct or indirect phosphorylation of PLC-γ2 (82). Reaction products of PLC, inositol 1,4,5-trisphosphate, and diacylglycerol, mobilize Ca2+ from intracellular storage sites and activate PKC, respectively (for review see reference 83). Increased Ca2+ concentrations also lead to the activation and nuclear translocation of NFAT by dephosphorylation of cytoplasmic NFAT by the calcium/calmodulin–dependent phosphatase, calcineurin (for review see reference 84).

Our recent data indicates that Btk regulates JNKs and, to a lesser extent, p38, representing two of the three major MAP kinases (i.e., ERKs, JNKs, and p38) that are activated upon FcεRI cross-linking (59). Thus, upon FcεRI cross-linking, xid and btk null mast cells exhibited much reduced JNK activation compared with wt mast cells. Notably, the activities of ERKs upon FcεRI cross-linking were not significantly different between wt and btk mutant mast cells. The activity of phospholipase A2, a key enzyme of arachidonic acid cascade, was shown to be regulated by ERK, which in turn is regulated by Syk in rat basophilic leukemia RBL-2H3 cells (85). Accordingly, the lack of effect of btk mutations on ERK activity after FcεRI cross-linking probably explains our finding that leukotriene levels released from btk null mast cells were similar to those from wt mast cells (data not shown). Similarly, we found that the transcriptional activity of a c-fos–luciferase construct was not affected by btk mutations in mast cells (c-fos is also downstream of ERK).

btk mutations would be expected to impair signaling through JNKs (59). Targets of JNK include the transcription factors c-Jun and ATF-2. JNK phosphorylates the critical residues of the activation domains of these proteins to activate them (8688). c-Jun and ATF-2, in cooperation with NFAT, were shown to bind to the CRE and κ3 sites, respectively, which are required for the induction of the TNF-α promoter (57, 58). In the case of the IL-2 gene, Fos–Jun heterodimers cooperatively bind with NFAT proteins at four of the five NFAT-binding sites in the IL-2 promoter (55). Taken together with these previous findings, our current data are consistent with the hypothesis that Btk can regulate two arms of the FcεRI signaling process, i.e., the PLC/Ca2+/PKC and JNK signaling pathways (Fig. (Fig.6).6).

Figure 6
Hypothetical scheme of the roles of Btk in FcεRI-mediated signal transduction. Phosphorylation at Tyr-551 by activated Lyn leads to activation of Btk. Activated Btk in turn may phosphorylate PLC-γ, leading to Ca2+ mobilization. ...

On the other hand, the regulation of FcεRI signaling is potentially very complex, and not all of these complexities are illustrated in Fig. Fig.6.6. For example, we found that the secretion of TNF-α and other cytokines upon FcεRI cross-linking was greater in mast cells that had been cultured in the presence of both IL-3 and SCF as compared with that in cells that had been cultured in IL-3 alone. This might reflect, at least in part, the phosphorylation and enzymatic activation of PLC-γ by c-Kit (89, 90), the receptor for SCF. JNK is also activated transiently by SCF stimulation of BMMCs (59). Therefore, SCF/c-Kit–dependent activation of both PLC/Ca2+/PKC and JNK pathways probably contributed to cytokine gene induction in mast cells that were maintained in IL-3 and SCF.

Acknowledgments

We thank Drs. Ken-ichi Arai, Takashi Yokota, and Lisako Tsuruta for plasmids. We thank Drs. Kimishige Ishizaka, Howard Grey, and Amnon Altman for critical reading of an early version of the manuscript.

Footnotes

1Abbreviations used in this paper: BMMC, bone marrow–derived cultured mast cells; Btk, Bruton's tyrosine kinase; ITAM, immunoreceptor tyrosine–based activation motif; NFAT, nuclear factor of activated T cells; PCA, passive cutaneous anaphylactic; PH, pleckstrin homology; PKC, protein kinase C; PLC, phospholipase C; PTK, protein tyrosine kinase; SCF, stem cell factor; SH, Src homology.

This study was partly supported by National Institutes of Health grants RO1 AI-33617 and RO1 AI-38348 (T. Kawakami) and R37 AI-23990 and RO1 CA-72074 (S.J. Galli) and is Publication No. 147 from the La Jolla Institute for Allergy and Immunology.

References

1. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328:257–265. [PubMed]
2. Beaven MA, Metzger H. Signal transduction by Fc receptors: the FcεRI case. Immunol Today. 1993;14:222–226. [PubMed]
3. Ravetch JV, Kinet J-P. Fc receptors. Annu Rev Immunol. 1991;9:457–492. [PubMed]
4. Reth M. Antigen receptor tail clue. Nature. 1989;338:383–384. [PubMed]
5. Cambier JC. New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL) Immunol Today. 1995;16:110. [PubMed]
6. Benhamou M, Gutkind JS, Robbins KC, Siraganian RP. Tyrosine phosphorylation coupled to IgE receptor–mediated signal transduction and histamine release. Proc Natl Acad Sci USA. 1990;87:5327–5330. [PMC free article] [PubMed]
7. Kawakami T, Inagaki N, Takei M, Fukamachi H, Coggeshall KM, Ishizaka K, Ishizaka T. Tyrosine phosphorylation is required for mast cell activation by FcεRI cross-linking. J Immunol. 1992;148:3513–3519. [PubMed]
8. Stephen V, Benhamou M, Gutkind JS, Robbins KC, Siraganian RP. FcεRI-induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells (RBL-2H3). Evidence for a novel signal transduction pathway unrelated to G protein activation and phosphatidylinositol hydrolysis. J Biol Chem. 1992;267:5434–5441. [PubMed]
9. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR. Multiple defects in the immune system of Lyn-defective mice, culminating in autoimmune disease. Cell. 1995;83:301–311. [PubMed]
10. Rivera V, Brugge JS. Clustering of Syk is sufficient to induce tyrosine phosphorylation and release of allergic mediators from rat basophilic leukemia cells. Mol Cell Biol. 1995;15:1582–1590. [PMC free article] [PubMed]
11. Zhang J, Berenstein EH, Evans RL, Siraganian RP. Transfection of Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. J Exp Med. 1996;184:71–79. [PMC free article] [PubMed]
12. Jouvin M-H, Adamczewski M, Numerof R, Letourneur O, Valle A, Kinet J-P. Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J Biol Chem. 1994;269:5918–5925. [PubMed]
13. Kihara H, Siraganian RP. Src homlogy 2 domains of Syk and Lyn bind to tyrosine-phosphorylated subunits of the high affinity IgE receptor. J Biol Chem. 1994;269:22427–22432. [PubMed]
14. Rowley RB, Burkhardt AL, Chao H-G, Matsueda GR, Bolen JB. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Igα/Igβ immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem. 1995;270:11590–11594. [PubMed]
15. Shiue L, Zoller MJ, Brugge JS. Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J Biol Chem. 1995;270:10498–10502. [PubMed]
16. Yamada N, Kawakami Y, Kimura H, Fukamachi H, Baier G, Altman A, Kato T, Inagaki Y, Kawakami T. Structure and expression of novel protein tyrosine kinases, Emb and Emt, in hematopoietic cells. Biochem Biophys Res Commun. 1993;192:231–240. [PubMed]
17. Tang B, Mano H, Yi HT, Ihle JN. Tec kinase associates with c-kit and is tyrosine phosphorylated and activated following stem cell factor binding. Mol Cell Biol. 1994;14:8432–8437. [PMC free article] [PubMed]
18. Kawakami Y, Yao L, Tsukada S, Witte ON, Kawakami T. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon FcεRI cross-linking. Mol Cell Biol. 1994;14:5108–5113. [PMC free article] [PubMed]
19. Kawakami Y, Yao L, Tashiro M, Gibson S, Mills GB, Kawakami T. Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/ Emt, upon FcεRI cross-linking on mast cells. J Immunol. 1995;155:3556–3562. [PubMed]
20. Eiseman E, Bolen JB. Engagement of the high-affinity IgE receptor activates srcprotein-related tyrosine kinases. Nature. 1992;355:78–80. [PubMed]
21. Hutchcroft JE, Geahlen RL, Deanin GG, Oliver JM. FcεRI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells. Proc Natl Acad Sci USA. 1992;89:9107–9111. [PMC free article] [PubMed]
22. Benhamou M, Ryba NJP, Kihara H, Nishikata H, Siraganian RP. Protein-tyrosine kinase p72sykin high affinity IgE receptor signaling. Identification as a component of pp72 and association with the receptor γ chain after receptor aggregation. J Biol Chem. 1993;268:23318–23324. [PubMed]
23. Tsukada S, Saffran D, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–290. [PubMed]
24. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, et al. The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233. [PubMed]
25. Thomas JD, Sideras P, Smith CIE, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 1993;261:355–358. [PubMed]
26. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, Mohr RN, Bazan JF, Howard M, Copeland NG, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodieficient XID mice. Science. 1993;261:358–361. [PubMed]
27. Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci USA. 1994;91:10606–10609. [PMC free article] [PubMed]
28. Saouaf SJ, Mahajan S, Rowley RB, Kut SA, Fargnoll J, Burkhardt AL, Tsukada S, Witte ON, Bolen JB. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci USA. 1994;91:9524–9528. [PMC free article] [PubMed]
29. de Weers M, Brouns GS, Hinshelwood S, Kinnon C, Schuurman RKB, Hendriks RW, Borst J. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem. 1994;269:23857–23860. [PubMed]
30. Santos-Argumedo L, Lund FE, Heath AW, Solvason N, Mu WW, Grimaldi JC, Parkhouse RME, Howard M. CD38 unresponsiveness of xid B cells implicates Bruton's tyrosine kinase (btk)as a regulator of CD38 induced signal transduction. Int Immunol. 1995;7:163–170. [PubMed]
31. Yamashita Y, Miyake K, Kikuchi Y, Takatsu K, Noda S, Kosugi A. A monoclonal antibody against a murine CD38 homologue delivers a signal to B cells for prolongation of survival and production against apoptosis in vitro: unresponsiveness of X-linked immunodeficient B cells. Immunology. 1995;85:248–255. [PMC free article] [PubMed]
32. Hasbold J, Klaus GGB. B cells from CBA/N mice do not proliferate following ligation of CD40. Eur J Immunol. 1994;24:152–157. [PubMed]
33. Sato S, Katagiri T, Takaki S, Kikuchi Y, Hitoshi Y, Yonehara S, Tsukada S, Kitamura D, Watanabe T, Witte ON, Takatsu K. IL-5 receptor–mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases. J Exp Med. 1994;180:2101–2111. [PMC free article] [PubMed]
34. Matsuda T, Takahashi-Tezuka M, Fukuda T, Okuyama Y, Fujitani Y, Tsukada S, Mano H, Hirai H, Witte ON, Hirano T. Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. Blood. 1995;85:627–633. [PubMed]
35. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moor KW, Howard M. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X-chromosome–linked immunodeficiency B cells. J Exp Med. 1990;172:1625–1631. [PMC free article] [PubMed]
36. August A, Gibson S, Kawakami Y, Kawakami T, Mills GB, Dupont B. CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci USA. 1994;91:9347–9351. [PMC free article] [PubMed]
37. Gibson S, August A, Kawakami Y, Kawakami T, Dupont B, Mills GB. The EMT/ITK/TSK (EMT) tyrosine kinase is activated during TCR signaling. J Immunol. 1996;156:2716–2722. [PubMed]
38. Liao XC, Littman DR. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity. 1995;3:757–769. [PubMed]
39. Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, Davidson L, Mueller S, Kantor AB, Herzenberg LA, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3:283–299. [PubMed]
40. Kerner JD, Appleby MW, Mohr RN, Chien S, Rawlings DJ, Maliszewski CR, Witte ON, Perlmutter RM. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity. 1995;3:301–312. [PubMed]
41. Inagaki N, Goto S, Nagai H, Koda A. Homologous passive cutaneous anaphylaxis in various strains of mice. Int Arch Allergy Appl Immunol. 1986;81:58–62. [PubMed]
42. Nagai H, Sakurai T, Inagaki N, Mori H. An immunopharmacological study of the biphasic allergic skin reaction. Biol Pharm Bull. 1995;18:239–245. [PubMed]
43. Yao L, Kawakami Y, Kawakami T. The pleckstrin homology domain of Btk tyrosine kinase interacts with protein kinase C. Proc Natl Acad Sci USA. 1994;91:9175–9179. [PMC free article] [PubMed]
44. Gibson S, Leung B, Squire JA, Hill M, Arima N, Gross P, Hogg D, Mills GB. Identification, cloning, and characterization of a novel human T-cell–specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. Blood. 1993;83:1561–1572. [PubMed]
45. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77:61–68. [PubMed]
46. Onishi M, Kinoshita S, Morikawa Y, Shibuya A, Phillips J, Lanier LL, Gorman DM, Nolan GP, Miyajima A, Kitamura T. Applications of retrovirus-mediated expression cloning. Exp Hematol. 1996;24:324–329. [PubMed]
47. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392–8396. [PMC free article] [PubMed]
48. Siraganian RP. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem. 1974;57:383–394. [PubMed]
49. Tsuruta L, Lee H-J, Masuda ES, Koyano-Nakagawa N, Arai N, Arai K, Yokota T. Cyclic AMP inhibits expresssion of the IL-2 gene through the nuclear factor of activated T cells (NF-AT) site, and transfection of NF-AT cDNAs abrogates the sensitivity of EL-4 cells to cyclic AMP. J Immunol. 1995;154:5255–5264. [PubMed]
50. Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras–activated protein kinase distinct from JNK and ERK. Nature. 1994;371:171–175. [PubMed]
51. Wershil BK, Wang Z-S, Gordon JR, Galli SJ. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell–dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor–α J Clin Invest. 1991;87:446–453. [PMC free article] [PubMed]
52. Inagaki N, Goto S, Yamasaki M, Nagai H, Koda A. Studies on vascular permeability increasing factors involved in 48-hour homologous PCA in the mouse ear. Int Arch Allergy Appl Immunol. 1986;80:285–290. [PubMed]
53. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45–53. [PubMed]
54. Shaw J-P, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science. 1988;241:202–205. [PubMed]
55. Rooney JW, Sun Y-L, Glimcher LH, Hoey T. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol Cell Biol. 1995;15:6299–6310. [PMC free article] [PubMed]
56. Goldfeld AE, McCaffrey PG, Strominger JL, Rao A. Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor α gene promoter. J Exp Med. 1993;178:1365–1379. [PMC free article] [PubMed]
57. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol. 1996;16:459–467. [PMC free article] [PubMed]
58. Tsai EY, Yie J, Thanos D, Goldfeld AE. Cell-type–specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/ JUN. Mol Cell Biol. 1996;16:5232–5244. [PMC free article] [PubMed]
59. Kawakami Y, Miura T, Bissonnette R, Hata D, Khan WN, Kitamura T, Maeda-Yamamoto M, Hartman SE, Yao L, Alt FW, Kawakami T. Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. Proc Natl Acad Sci USA. 1997;94:3938–3942. [PMC free article] [PubMed]
60. Li T, Tsukada S, Satterthwaite A, Havlik MH, Park H, Takatsu K, Witte ON. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity. 1995;2:1–20. [PubMed]
61. Clark SG, Stern MJ, Horvitz HR. C. elegans cell-signalling gene sem-5 encodes a protein with SH2 and SH3 domains. Nature. 1992;356:340–344. [PubMed]
62. Conley ME, Parolini O, Rohrer J, Campana D. X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene. Immunol Rev. 1994;138:5–21. [PubMed]
63. Scher I. The CBA/N mouse strain: an experimental model illustrating the influence of X chromosome on immunity. Adv Immunol. 1982;33:1–71. [PubMed]
64. Harlan JE, Hajduk PJ, Yoon HS, Fesik SW. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature. 1994;371:168–170. [PubMed]
65. Salim K, Bottomley MJ, Querfurth E, Zvelebil MJ, Gout I, Scaife R, Margolis RL, Gigg R, Smith CIE, Driscoll PC, et al. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO (Eur Mol Biol Organ) J. 1996;15:6241–6250. [PMC free article] [PubMed]
66. Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-terakisphosphate binding capacity. J Biol Chem. 1996;271:30303–30306. [PubMed]
67. Touhara K, Inglese J, Pitcher JA, Shaw G, Lefkowitz RJ. Binding of G protein βγ-subunits to pleckstrin homology domains. J Biol Chem. 1994;269:10217–10220. [PubMed]
68. Wang D-S, Shaw R, Winkelmann JC, Shaw G. Binding of PH domains of β-adrenergic receptor kinase and β-spectrin to WD40/β-transducin repeat containing regions of the β-subunit of trimeric G-proteins. Biochem Biophys Res Commun. 1994;203:29–35. [PubMed]
69. Yang W, Desiderio S. BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci USA. 1997;94:604–609. [PMC free article] [PubMed]
70. Cheng G, Ye Z-S, Baltimore D. Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain–mediated interaction. Proc Natl Acad Sci USA. 1994;91:8152–8155. [PMC free article] [PubMed]
71. Yang W, Malek SN, Desiderio S. An SH3-binding site conserved in Bruton's tyrosine kinase and related tyrosine kinases mediates specific protein interactions in vitro and in vivo. J Biol Chem. 1995;270:20832–20840. [PubMed]
72. Cory GOC, Lovering RC, Hinshelwood S, MacCarthy-Morrogh L, Levinsky RJ, Kinnon C. The protein product of the c-cblprotooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase. J Exp Med. 1995;182:611–615. [PMC free article] [PubMed]
73. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 1989;244:339–343. [PubMed]
74. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA. 1986;83:1670–1674. [PMC free article] [PubMed]
75. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977–980. [PubMed]
76. Han J, Brown T, Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med. 1990;171:465–475. [PMC free article] [PubMed]
77. Goldfeld AE, Tsai EY, Kincaid R, Belshaw PJ, Schreiber SL, Strominger JL, Rao A. Calcineurin mediates human tumor necrosis factor α gene induction in stimulated T and B cells. J Exp Med. 1994;180:763–768. [PMC free article] [PubMed]
78. Prieschl EE, Pendl GG, Harrer NE, Baumruker T. p21raslinks FcεRI to NF-AT family member in mast cells. The AP3-like factor in this cell type is an NF-AT family member. J Immunol. 1995;155:4963–4970. [PubMed]
79. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran T, Rao A. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature. 1993;365:352–355. [PubMed]
80. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, Fluckiger A-C, Witte ON, Kinet J-P. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 1996;271:822–825. [PubMed]
81. Park H, Wahl MI, Afar DEH, Turck CW, Rawlings DJ, Tam C, Scharenberg AM, Kinet J-P, Witte ON. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996;4:515–525. [PubMed]
82. Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor–mediated activation of phospholipase C-γ2. J Exp Med. 1996;184:31–40. [PMC free article] [PubMed]
83. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984;308:693–698. [PubMed]
84. Rao A. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today. 1994;15:274–281. [PubMed]
85. Hirasawa N, Scharenberg AM, Yamamura H, Beaven MA, Kinet J-P. A requirement for Syk in the activation of the microtubule-associated protein kinase/phopholipase A2pathway by FcεRI is not shared by a G protein–coupled receptor. J Biol Chem. 1995;270:10960–10967. [PubMed]
86. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science. 1995;267:389–393. [PubMed]
87. Livingstone C, Patel G, Jones N. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO (Eur Mol Biol Organ) J. 1995;14:1785–1797. [PMC free article] [PubMed]
88. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-juninduction in response to genotoxic agents. EMBO (Eur Mol Biol Organ) J. 1995;14:1798–1811. [PMC free article] [PubMed]
89. Lev S, Givol D, Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO (Eur Mol Biol Organ) J. 1991;10:647–654. [PMC free article] [PubMed]
90. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DE, Bernstein A, Pawson T. Signal transduction by normal isoforms and Wmutant variants of the Kit receptor tyrosine kinase. EMBO (Eur Mol Biol Organ) J. 1991;10:2451–2459. [PMC free article] [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...